PD-1 and PD-L1 inhibitors in oesophago-gastric cancers

Telli, Tuğba Akın; Bregni, Giacomo; Camera, S.; Deleporte, Amélie; Hendlisz, Alain; Sclafani, Francesco

doi:10.1016/j.canlet.2019.10.036

Cited by 42 publications

(35 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is likely that other checkpoint inhibitor pathways might play a role in the inhibition of effector T‐cell function of cervical cancer with HPV. PD‐1/PD‐L1 inhibitory pathway has been found in a variety of tumors and has become a target for immunotherapy 37‐39 . We have confirmed in a previous study that PD‐1 is overexpressed on the surface of CD4+ T and CD8+ T cells, which binds to PD‐L1 ligands on the surface of DCs and mediates T‐cell disability 6 .…”

Section: Discussionsupporting

confidence: 81%

“…PD-1/PD-L1 inhibitory pathway has been found in a variety of tumors and has become a target for immunotherapy. [37][38][39] We have confirmed in a previous study that PD-1 is overexpressed on the surface of CD4+ T and CD8+ T cells, which binds to PD-L1 ligands on the surface of DCs and mediates T-cell disability. 6 At least two different pathways of Tim-3/Galectin-9 and PD-1/PD-L1 play a role in inhibiting T-cell function in the occurrence of cervical cancer.…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

The role of Tim‐3/Galectin‐9 pathway in T‐cell function and prognosis of patients with human papilloma virus‐associated cervical carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 79%

The role of Tim‐3/Galectin‐9 pathway in T‐cell function and prognosis of patients with human papilloma virus‐associated cervical carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Immune evasion and abnormal immune surveillance of cancers play a crucial role in carcinogenesis and cancer progression ( Dunn et al, 2002 ). The role of programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) in the immune escape of cancer cells makes them promising targets of cancer therapy ( Ghahremanloo et al, 2019 ; Akin Telli et al, 2020 ). Recently, blockades of the PD-1/PD-L1 axis have been proven to be successful in the treatment of solid tumors ( Liu, 2019 ; Liu et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia

Chen

Gao

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. However, the clinical response to PD-1/PD-L1 blockade varied in patients with acute myeloid leukemia (AML). It is thought that there are factors other than PD-1 and PD-L1 that may affect the effect of immunotherapy. This study explored the impact of transcriptome-based co-expression of bromodomain containing 4 (BRD4) and PD-1/PD-L1 on the overall survival (OS) of patients with AML, in order to understand whether BRD4 would affect the effect of PD-1/PD-L1 blockades. Bone marrow samples from 59 AML patients in our clinical center and data of 176 patients from the Cancer Genome Atlas (TCGA) database were used for OS analysis and validation. It was found that increased expression of BRD4 was associated with poor OS in AML patients. Moreover, co-expression of BRD4 with PD-1 or PD-L1 was related to poor OS. The co-expression of BRD4 and PD-L1 was better than BRD4 and PD-1 for OS prediction. Furthermore, co-expression of BRD4 and PD-L1 was positively correlated with high tumor mutation burden, which contributed to poor OS in AML patients. Additionally, the co-expression of BRD4 and PD-L1 was associated with poor OS in non-acute promyelocytic leukemia patients with intermediate/high risk or under 60 years. Our results suggest that transcriptome-based co-expression of BRD4 and PD-L1 is a predictor for poor OS in AML patients, which might provide novel insight into designing combinational targeted therapy for AML.

show abstract

“…A diagnostic indicator is important in the prediction of tumor immunotherapy efficiency, which predicts whether patients may benefit from treatment and provides ways in which to choose a more suitable treatment for patients 10,11 . For example, PD‐1 is an effective target for tumor immunotherapy, however fewer than 20% of patients benefit from this therapy, and the immune mechanisms involved in the response to these therapeutic interventions remain poorly elucidated, especially in non–small‐cell lung cancers and esophagus‐gastric cancers 12,13 . The infiltration of immune cells in tumor sites is the basis for effective immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration

Zhang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

Immune cell infiltration is an important indicator of whether tumor patients will benefit from immunotherapy. Gastric cancer is one of the most common tumors in the world, and new indicators of immunotherapy are urgently needed. The aim of this study was to construct ceRNA networks in gastric cancer with different degrees of immune cell infiltration. We analyzed the expression profiles of different gastric cancer with different degrees of immune cell infiltration retrieved from The Cancer Genome Atlas (TCGA) database and found differentially expressed lncRNAs, mRNAs, and miRNAs. A ceRNA regulatory network of gastric cancer with different degrees of immune cell infiltration was constructed using functional annotation, RNA‐RNA interaction prediction, correlation analysis, survival analysis, and other comprehensive bioinformatics methods. The interaction and correlation between ceRNAs were verified using experiments on tumor tissues and cell lines. Cell line experiments showed a potential RP11‐1094M14.8/miR‐1269a/CXCL9 axis that was consistent with the ceRNA theory. qRT‐PCR results showed that RP11‐1094M14.8 knockdown significantly reduced the expression of CXCL9, and RP11‐1094M14.8 overexpression had the opposite effect. The results of clinical analysis of gastric cancer samples showed that RP11‐1094M14.8 and CXCL9 were highly expressed in hot tumors, and CXCL9 was positively correlated with a better prognosis for patients. The constructed novel ceRNA network and the potential regulatory axis may provide a comprehensive understanding of the potential mechanisms of development in gastric cancer with different degrees of immune cell infiltration. The RP11‐1094M14.8/miR‐1269a/CXCL9 axis may serve as a potential immune‐therapeutic target for gastric cancer with different degrees of immune cell infiltration.

show abstract

PD-1 and PD-L1 inhibitors in oesophago-gastric cancers

Cited by 42 publications

References 73 publications

The role of Tim‐3/Galectin‐9 pathway in T‐cell function and prognosis of patients with human papilloma virus‐associated cervical carcinoma

The role of Tim‐3/Galectin‐9 pathway in T‐cell function and prognosis of patients with human papilloma virus‐associated cervical carcinoma

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia

A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration

Contact Info

Product

Resources

About